ARS Pharmaceuticals, Inc.
SPRYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. With a market capitalization of $400.8M, it sits in small-cap territory. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Market Cap
$400.8M
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
-4.49
EPS (TTM)
$-2.18
EPS (Fwd)
$-0.90
ROE
-210.3%
ROA
-48.0%
Cash
$143.8M
Total Debt
$171.6M
Free CF
-$117.7M
52W Change
-57.9%
Annual Financials
Cash vs Debt
Where SPRY stands vs its 150-day and 200-day moving averages
As of the October 2, 2026 close, SPRY finished 44.17% below its 150-day moving average ($7.38) and 49.39% below its 200-day moving average ($8.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SPRY overbought or oversold?
At the October 2, 2026 close, SPRY's RSI(14) was 34.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ARS Pharmaceuticals, Inc. carries $171.6M in total debt against $143.8M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$117.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -210.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $1.3M to $84.3M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ARS Pharmaceuticals, Inc.'s trajectory.